The day in pharma, read in minutes.
NewsEktaH Advances NKS-3 Obesity Drug into Phase IIa
EktaH enrolls first patient in Phase IIa obesity trial in Tunisia, backed by €2.4M in new funding for NKS-3.
Innate Pharma Reports Phase 1 Results for IPH4502 ADC

Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib

FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA

FDA Draft Guidance Sets Bayesian Methods for Drug Trials

Latest news
11 storiesNuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC
FDA grants neladalkib accelerated approval for ALK-positive NSCLC, triggering confirmatory trial and manufacturing scale-up obligations for Nuvalent.

Mandos Secures FDA Approval for Lembaz in Infantile-Onset NPC
FDA approves Lembaz for infantile-onset NPC using external control survival data, setting a precedent for rare disease regulatory strategy.

Viatris Completes $1.65B Acquisition of Pacira BioSciences
Viatris completes Pacira BioSciences acquisition, adding EXPAREL and iovera° and triggering NDA transfer and manufacturing integration work.

Greenwich LifeSciences Gets Two Abstracts Accepted for SABCS 2026
Greenwich LifeSciences secures two SABCS 2026 abstract acceptances for its Fast Track-designated GLSI-100 Phase III breast cancer immunotherapy trial.

Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board
Hikma Pharmaceuticals names former Cipla CEO Umang Vohra to its Board and Audit Committee.

Bioxcel Therapeutics Gains FDA Approval for First At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Bioxcel Therapeutics wins FDA approval for the first at-home agitation treatment, raising GMP and combination product compliance questions for CNS manufacturers.

IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy
IDEAYA Biosciences aligns with FDA on a dual-track IDE849 strategy: single-arm accelerated approval cohort plus concurrent Phase 3 in neuroendocrine carcinomas.

FDA Approves Giredestrant Plus Everolimus for Breast Cancer
FDA approves Genentech's giredestrant plus everolimus for ESR1-mutated metastatic breast cancer, with FoundationOne Liquid CDx as mandatory companion diagnostic.

Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing
Cue Biopharma's Phase 2 CSU data show durable IgE suppression 12 weeks post-dose; CUE-401 enters first-in-human dosing in Q3 2026.

Mankind Pharma Secures Exclusive India Rights for Ensartinib
Mankind Pharma secures exclusive India commercialisation rights for Betta's FDA-approved ALK inhibitor Ensartinib, targeting ALK-positive NSCLC patients.

Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET
Lantheus presents Phase 3 data for TAUKLARIFY tau-PET agent, meeting all sensitivity and specificity endpoints across 617 scans in early Alzheimer's disease.

Worth your time this week

UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor

Novartis Gains Positive CHMP Opinion for Cosentyx in Adolescents

Evotec Secures $2.9M Grant for Stem Cell Fetal Safety
